Report cover image

Global Benign Prostatic Hyperlasia Treatment Market -Global Trends and Forecasts(2025 to 2034)

Publisher Factview Research
Published Nov 02, 2025
Length 107 Pages
SKU # FAVR20572900

Description

Benign Prostatic Hyperplasia Treatment Market Size And Forecast

According to Factview Research, Global Benign Prostatic Hyperplasia Treatment Market was valued at USD 11.83 Billion in 2024 and is projected to reach USD 24.08 Billion by 2034, growing at a CAGR of 8.2% from 2025 to 2034.

Global Benign Prostatic Hyperplasia Treatment Market Outlook

The increasing population of elderly men, the acceptance of unhealthy lifestyle among the people are the key factor for driving the growth of the market. In addition, the growing health awareness and early diagnosis of the medical condition fueling the demand for the treatment and thereby contributing to propel the market growth. However, the huge price involves the benign prostatic hyperplasia treatment, expected to hamper the market growth.

Global Benign Prostatic Hyperplasia Treatment Market Competitive Landscape

The Global Benign Prostatic Hyperplasia Treatment Market study report will provide a valuable insight with an emphasis on Global market including some of the major players such as Abbott Laboratories, Astellas Pharma Inc., Eli Lilly and Company, Merck & Co., Inc., Sanofi, Allergan plc, Boehringer Ingelheim Pharma GmbH & Co. KG, GlaxoSmithKline plc, Pfizer Inc, and Teva Pharmaceutical Industries Limited.

Table of Contents

107 Pages
1 Introduction Of Global Benign Prostatic Hyperplasia Treatment Market
1.1 Overview Of The Market
1.2 Scope Of Report
1.3 Assumptions
2 Executive Summary
3 Research Methodology Of Factview Research
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List Of Data Sources
4 Global Benign Prostatic Hyperplasia Treatment Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Benign Prostatic Hyperplasia Treatment Market, By Product Type
5.1 Overview
5.2 5-alpha Reductase Inhibitor
5.3 Alpha Blocker
5.4 Phosphodiesterase-5 Inhibitor
5.5 Others
6 Global Benign Prostatic Hyperplasia Treatment Market, By Therapy
6.1 Overview
6.2 Combination Drug Therapy
6.3 Mono Drug Therapy
7 Global Benign Prostatic Hyperplasia Treatment Market, By Geography
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Rest Of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest Of Asia Pacific
7.5 Rest Of The World
7.5.1 Latin America
7.5.2 Middle East
8 Global Benign Prostatic Hyperplasia Treatment Market Competitive Landscape
8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies
9 Company Profiles
9.1 Abbott Laboratories
9.1.1 Overview
9.1.2 Financial Performance
9.1.3 Product Outlook
9.1.4 Key Developments
9.2 Astellas Pharma Inc.
9.2.1 Overview
9.2.2 Financial Performance
9.2.3 Product Outlook
9.2.4 Key Developments
9.3 Eli Lilly And Company
9.3.1 Overview
9.3.2 Financial Performance
9.3.3 Product Outlook
9.3.4 Key Developments
9.4 Merck &Amp; Co., Inc.
9.4.1 Overview
9.4.2 Financial Performance
9.4.3 Product Outlook
9.4.4 Key Developments
9.5 Sanofi
9.5.1 Overview
9.5.2 Financial Performance
9.5.3 Product Outlook
9.5.4 Key Developments
9.6 Allergan Plc
9.6.1 Overview
9.6.2 Financial Performance
9.6.3 Product Outlook
9.6.4 Key Developments
9.7 Boehringer Ingelheim Pharma Gmbh &Amp; Co. Kg
9.7.1 Overview
9.7.2 Financial Performance
9.7.3 Product Outlook
9.7.4 Key Developments
9.8 Glaxosmithkline Plc
9.8.1 Overview
9.8.2 Financial Performance
9.8.3 Product Outlook
9.8.4 Key Developments
9.9 Pfizer Inc
9.9.1 Overview
9.9.2 Financial Performance
9.9.3 Product Outlook
9.9.4 Key Developments
9.10 Teva Pharmaceutical Industries Limited
9.10.1 Overview
9.10.2 Financial Performance
9.10.3 Product Outlook
9.10.4 Key Developments
10 Appendix
10.1 Related Research

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us